[Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
The most aggressive and rare manifestation of multiple myeloma is plasma cell leukaemia (PCL). While secondary form of PCL represents those heavily pretreated cases when leukaemic transformation develops terminally after intensive chemotherapy in patients with multiple myeloma, primary cases are characterized by leukaemic symptoms present at diagnosis. The secondary form has a rapid progression. The management of PCL is still unsolved. The authors present a case of a patient with non-secretory multiple myeloma who had developed plasma cell leukaemia after peripheral stem cell transplantation. PAD (bortezomib, doxorubicin, dexamethasone) treatment resulted in complete remission and 9-month survival of the patient. Previous case reports in the literature and our experience have revealed PAD protocol to be well tolerated and effective in PCL. Combination of PAD treatment with autologous and/or allogenic stem cell transplantation might further improve patients' outcome.
Telek
Béla
B
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar II. Belgyógyászati Klinika, Hematológiai Tanszék Debrecen Pf. 20. 4012. btelek@dote.hu
Méhes
Leonóra
L
Batár
Péter
P
Kiss
Attila
A
Udvardy
Miklós
M
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000601:surgery; D036102:Peripheral Blood Stem Cell Transplantation; D011719:Pyrazines / Q000008:administration & dosage; D012074:Remission Induction; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin
Autológ ossejt-transzplantációt követoen kialakult plazmasejtes leukémia hatékony kezelése PAD- (bortezomib, doxorubicin, dexamethason) protokoll alkalmazásával.